Kadmon Holdings, Inc.

Investors that purchased the Company’s securities and have suffered a loss, please fill in transaction information below, or email to info@portnoylaw.com.

Are you a current or former employee of the company?*YesNo


+Additional Purchases


+Additional Sales

If you prefer, you may submit your transaction information or comments/questions in the box below:

There is no cost or obligation associated with submitting your information. If you are a shareholder who suffered a loss, please submit your contact information and purchase information to participate in the putative class action.

We also encourage you to contact Lesley F. Portnoy of The Portnoy Law Firm, at 310.692.8883, to discuss your rights free of charge. You can also reach us through the firm’s website at www.portnoylaw.com, or by email at info@portnoylaw.com.

If you choose to take no action, you can remain an absent class member.

Joining the case through the Portnoy Law website enables investors to learn about their legal claims and take an active role in recovering their losses.

The Portnoy Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.

Portnoy Law Firm
Lesley F. Portnoy, Esq.,
Office: 310.692.8883
1800 Century Park East, Suite 600
Los Angeles, CA 90067

It is alleged in this complaint that Kadmon made misleading and/or false statements and/or failed to disclose that: (1) the NDA for belumosudil for the treatment of chronic graft-versus-host disease (cGVHD) with the U.S. Food and Drug Administration was deficient and/or incomplete; (2) the additional data that Kadmon submitted in support of the Belumosudil NDA in response to an information request from the FDA materially altered the submission of the  Belumosudil NDA; (3) accordingly, the initial Belumosudil NDA submission lacked the degree of support that investors were led to believe by Kadmon; (4) accordingly, it was likely that the FDA would extend the Prescription Drug User Fee Act target action date in order to review the Belumosudil NDA; and (5) defendants’ public statements were materially false and misleading at all relevant times, as a result. The lawsuit claims that investors suffered damages, when the true details entered the market,